| 000 | 00825 a2200229 4500 | ||
|---|---|---|---|
| 005 | 20250518060749.0 | ||
| 264 | 0 | _c20200206 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1523-5866 | ||
| 024 | 7 |
_a10.1093/neuonc/noz146 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMolinaro, Annette M | |
| 245 | 0 | 0 |
_aEGFR amplification status for clinical trial inclusion: where do we draw the line? _h[electronic resource] |
| 260 |
_bNeuro-oncology _c10 2019 |
||
| 300 |
_a1215-1216 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aErbB Receptors _xgenetics |
| 650 | 0 | 4 | _aGene Amplification |
| 700 | 1 | _aPhillips, Joanna J | |
| 773 | 0 |
_tNeuro-oncology _gvol. 21 _gno. 10 _gp. 1215-1216 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/neuonc/noz146 _zAvailable from publisher's website |
| 999 |
_c30096114 _d30096114 |
||